Drug Combination Details
| General Information of the Combination (ID: C57493) | |||||
|---|---|---|---|---|---|
| Name | Glatiramer acetate NP Info | + | Atorvastatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Multiple sclerosis
[ICD-11: 8A40]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | IL10 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | IL12A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TNF | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Female (PL/J * SJL/J)mice were immunized with MBP Ac1-11 (100 ug) to establish the animal model. | |||||
| Experimental
Result(s) |
Monocytes treated with the combination of suboptimal doses of atorvastatin and GA secreted an antiinflammatory type II cytokine pattern and, when used as APCs, promoted Th2 differentiation of naive myelin-specific T cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest. 2006 Apr;116(4):1037-44. | |||
